What question did this study set out to answer?

This research aims to evaluate the effectiveness of second-line and subsequent therapies after first-line treatment failure in advanced hepatocellular carcinoma.

April 10, 2026Open Access

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Key Points

This research aims to evaluate the effectiveness of second-line and subsequent therapies after first-line treatment failure in advanced hepatocellular carcinoma.
Multicenter prospective cohort study design
Focus on patients with advanced hepatocellular carcinoma
Assessment of therapies including lenvatinib and regorafenib
Evaluation of progression-free survival and overall survival metrics
Second-line lenvatinib treatment was associated with prolonged progression-free survival
Third-line regorafenib treatment improved overall survival
Findings highlight the importance of optimizing sequential treatments for better patient outcomes

Abstract

In advanced HCC following 1L AtezoBev failure, 2L lenvatinib prolonged PFS, and 3L regorafenib improved OS. These findings underscore the need to optimize sequential systemic therapies to enhance survival.

Bookmark

View Full Paper